Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer

Small-cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by a rapid initial response and early development of resistance to systemic therapy and radiation. The management of SCLC significantly changed for the first time in decades with the introduction of immune checkpoint...

Descripción completa

Detalles Bibliográficos
Autores principales: Riano, Ivy, Patel, Shruti R., Liu, Stephen V., Duma, Narjust
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293071/
https://www.ncbi.nlm.nih.gov/pubmed/34287275
http://dx.doi.org/10.3390/clinpract11030059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293071/
https://www.ncbi.nlm.nih.gov/pubmed/34287275
http://dx.doi.org/10.3390/clinpract11030059

Ejemplares similares